` PHO (Photocure ASA) vs Oslo OBX Comparison - Alpha Spread

PHO
vs
Oslo OBX

Over the past 12 months, PHO has underperformed Oslo OBX, delivering a return of 8% compared to the Oslo OBX's 15% growth.

Stocks Performance
PHO vs Oslo OBX

Loading

Performance Gap
PHO vs Oslo OBX

Loading
PHO
Oslo OBX
Difference

Performance By Year
PHO vs Oslo OBX

Loading
PHO
Oslo OBX
Add Stock

Competitors Performance
Photocure ASA vs Peers

Oslo OBX
PHO
LLY
JNJ
NOVO B
ROG
Add Stock

Photocure ASA
Glance View

Market Cap
1.6B NOK
Industry
Pharmaceuticals

Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

PHO Intrinsic Value
72.98 NOK
Undervaluation 21%
Intrinsic Value
Price
Back to Top